Mylan Inc (MYL) Price: $22.98

Industry: DrugsChaikin Power Gauge Report | Generated: Mon Mar 26 12:22 EDT 2012

Power Gauge Rating

MYL Mylan Inc

News Sentiment :Positive

March 21, 2012

News Sentiment Rating

Bullish

Chaikin Sentiment GaugeTM

for MYL is bullish. There is currently a significantpositive sentiment within news stories concerning MYL.

Power Trend - 5 Year Chart

The Power Gauge distills a 20 factor model into a concise picture of a stock's potential. High Potential Neutral Low Potential

MYL - Bullish

The Chaikin Power Gauge RatingTM

for MYL is bullish due to very strongearnings performance and bullish price/volume activity. The rating also reflectsnegative expert opinions.

MYL's earnings performance is very strong as a result of an upward trend inearnings this year and a relatively low projected P/E ratio.

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here www.chaikinpowertools.com

Financials & Earnings

Business Value

Price to Sales Ratio

Return on Equity

Price to Book Value

LT Debt/Equity Ratio

Financial Metrics Financial Metrics Rating

Assets and Liabilities Valuation Returns

Neutral

MYL's financial metrics are neutral. The company has high revenue per shareand is carrying too much long term debt relative to its industry group.

The rank is based on a high long term debt to equity ratio relative to its industrygroup, high price to book value ratio, high return on equity, low price to sales ratioand relatively low cash flow.

Ratio TTM

Current Ratio 1.39

LT Debt/Equity 1.38

Ratio TTM

Price/Book 2.80

Price/Sales 1.60

Ratio TTM

Return on Invest 10.6%

Return on Equity 24.2%

Earnings Consistency

Projected P/E Ratio

Earnings Trend

Earnings Surprise

Earnings Growth

Earnings Performance Earnings Performance Rating

5 Year Revenue and Earnings Growth EPS Estimates

EPS Surprise EPS Quarterly Results

Very Bullish

MYL's earnings performance has been very strong. The company experiencedsuperior earnings growth in the past 12 months and is priced relatively lowcompared to next year's projected EPS.

The rank is based on an upward trend in earnings this year, a relatively lowprojected P/E ratio and consistent earnings over the past 5 years.

12/07 12/08 12/09 12/10 12/11

Revenue(M) 2,666.02 5,137.58 5,092.78 5,450.52 6,129.82

Rev % Growth 65.40% 92.71% -0.87% 7.02% 12.46%

EPS $-4.91 $-1.05 $0.31 $0.69 $1.25

EPS % Growth -586.14% 78.62% 129.52% 122.58% 81.16%

Factor Actual EPS Prev EST EPS Current Change

Quarterly EPS $0.24 $0.52 +0.28

Yearly EPS $1.25 $2.44 +1.19

Factor Actual EPS Growth Est EPS Growth Change

3-5 year EPS 35.35% 9.51% -25.84

Estimate Actual Difference % Difference

Latest Qtr $0.50 $0.53 $0.03 6.00

1 Qtr Ago $0.51 $0.55 $0.04 7.84

2 Qtr Ago $0.45 $0.52 $0.07 15.56

3 Qtr Ago $0.44 $0.44 $0.00 0.00

FY Qtr 1 Qtr 2 Qtr 3 Qtr 4 Total

12/09 $0.23 $0.19 $-0.13 $0.01 $0.30

12/10 $0.20 $0.17 $0.35 $0.01 $0.73

12/11 $0.24 $0.34 $0.37 $0.30 $1.25

Fiscal Year End Month is December.

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here www.chaikinpowertools.com

Price Trend & Expert Opinions

Volume Trend

Price Trend ROC

Price Trend

Chaikin Money Flow

Relative Strength vs Market

Price/Volume Activity Price/Volume Activity Rating

Relative Strength vs S&P500 Index

Chart shows whether MYL is performing better or worse than the market.

Chaikin Money Flow

Chaikin Money Flow analyzes supply and demand for a company's stock.

Price Activity Price Activity Volume Activity

Bullish

Price and volume activity for MYL is bullish. MYL is experiencing sustainedbuying and has outperformed the S&P 500 over 26 weeks.

The rank for MYL is based on positive Chaikin money flow.

Factor Value

52 Week High 25.23

52 Week Low 16.16

% Change YTD Rel S&P 500 -4.47%

Factor Value

% Change Price - 4 Weeks -3.00%

% Change Price - 24 Weeks 31.01%

% Change Price - 4 Wks Rel to S&P -5.33%

% Change Price - 24 Wks Rel to S&P 9.25%

Factor Value

Average Volume 20 Days 5,238,400

Average Volume 90 Days 5,543,251

Chaikin Money Flow Persistency 69%

Relative Strength vs Industry

Analyst Opinions

Insider Activity

Short Interest

Earnings Estimate Revisions

Expert Opinions Expert Opinions

Earnings Estimate Revisions Analyst Recommendations EPS Estimates Revision Summary

Bearish

Expert opinions about MYL are negative. Analysts's opinions on MYL have beenmore negative recently and short interest in MYL is high.

The rank for MYL is based on analysts revising earnings estimates upward, ahigh short interest ratio, insiders purchasing stock, pessimistic analyst opinionsand relative weakness of the stock versus the Drugs industry group.

Current 7 Days Ago % Change

Current Qtr 0.52 0.52 0.00%

Next Qtr 0.58 0.58 0.00%

Current 30 Days Ago % Change

Current FY 2.44 2.43 0.01

Factor Value

Mean this Week Buy

Mean Last Week Buy

Change 0.00

Mean 5 Weeks Ago Buy

Last Week Last 4 Weeks

Up Down Up Down

Curr Qtr 0 1 0 3

Curr Yr 0 0 1 0

Next Qtr 1 0 1 2

Next Yr 0 0 2 0

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here www.chaikinpowertools.com

The Company & Its Competitors

MYL's Competitors in Drugs

Company Power Historic EPS Projected EPS Profit Margin PEG PE Revenue(M)Gauge growth growth

MYL 35.35% 9.51% 8.76% 0.99 11.26 6,130

IPXL 50.69% 15.61% 12.77% 0.86 24.09 513

WPI 18.82% 8.68% 5.69% 1.31 13.70 4,584

TEVA 16.94% 8.40% 15.07% 0.92 8.65 18,312

PRX 12.80% 7.76% -2.82% 1.35 11.20 926

RDY 38.12% 25.00% 15.63% 0.70 19.28 1,677

SCR 14.96% 5.17% 8.74% 3.94 21.51 324

HITK 24.65% - 22.59% - 9.20 191

News Headlines for MYL

BRIEF: Mylan receives approval for genericBoniva - Mar 21, 2012

Mylan One of First to Launch Generic Version ofBoniva® - Mar 20, 2012

Mylan Canada Receives Health CanadaApproval for Generic Version of Crestor® - Mar15, 2012

Mylan Launches First Equivalent Product toLexapro® Tablets - Feb 29, 2012

Mylan Receives Tentative FDA ApprovalThrough PEPFAR for Pediatric HIV/AIDSTherapy - Feb 23, 2012

Company Details Company Profile

Mylan Inc1500 CORPORATE DRIVE SUITE400CANONSBURG, PA 15317USAPhone: 724-514-1800Fax: 724-514-1870Website:http://http://www.mylan.comFull Time Employees: 18,000Sector: Medical

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceuticalcompanies. The Company offers one of the industry's broadest and highest qualityproduct portfolios, a robust product pipeline and a global commercial footprint throughoperations in more than 90 countries. Through its controlling interest in MatrixLaboratories Limited, Mylan has direct access to one of the largest active pharmaceuticalingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialtybusiness, provides the Company with innovative and diversified opportunities in therespiratory and allergy therapeutic areas.

Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculatedby evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is thestrongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe.

Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with anystate securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the informationincluded herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as anendorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual.The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investmentdecisions.

Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes theconfidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered byZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not beresponsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is noguarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools.

This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.

LM 2.3 DS 3.0 LS 2.1

Data Provided by ZACKS Investment Research, Inc., www.zacks.com Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com